At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Oral EP262 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)
In Brief
A Phase 2 clinical trial evaluating Oral EP262 and Placebo for Atopic Dermatitis. Completed, enrolled 32 participants across 10 sites in 2 countries.
Detailed Summary
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedNov 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedNov 22, 2023
Enrollment StartOct 25, 2023
Primary CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.6 years ago
Interventions
Oral EP262drug
Once daily
Placebodrug
Once Daily